These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22987989)

  • 21. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience.
    Chau C; Cathomas R; Wheater M; Klingbiel D; Fehr M; Bennett J; Markham H; Lee C; Crabb SJ; Geldart T
    Ann Oncol; 2015 Sep; 26(9):1865-1870. PubMed ID: 26037797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer.
    Boulos S; Mazhar D; Warren AY; Wong HH
    Future Oncol; 2017 May; 13(11):947-950. PubMed ID: 28481147
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of Low-Stage Testicular Seminoma.
    Pearce SM; Liauw SL; Eggener SE
    Urol Clin North Am; 2015 Aug; 42(3):287-98. PubMed ID: 26216816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
    Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
    Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
    Aparicio J; Germà JR; García del Muro X; Maroto P; Arranz JA; Sáenz A; Barnadas A; Dorca J; Gumà J; Olmos D; Bastús R; Carles J; Almenar D; Sánchez M; Paz-Ares L; Satrústegui JJ; Mellado B; Balil A; López-Brea M; Sánchez A;
    J Clin Oncol; 2005 Dec; 23(34):8717-23. PubMed ID: 16260698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy for metastatic germ cell tumours of the testis].
    Culine S
    Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is surveillance for stage 1 germ cell tumours of the testis appropriate outside a specialist centre?
    Jones A; Fergus JN; Chapman J; Houghton L
    BJU Int; 1999 Jul; 84(1):79-84. PubMed ID: 10444129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
    Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
    Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selected use of aggressive adjuvant chemotherapy in resected stage II nonseminomatous germ cell tumors of the testis.
    Pizzocaro G
    Prog Clin Biol Res; 1985; 203():585-90. PubMed ID: 2421344
    [No Abstract]   [Full Text] [Related]  

  • 34. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer.
    Abratt RP; Pontin AR; Barnes RD; Reddi BV
    S Afr Med J; 1994 Sep; 84(9):605-7. PubMed ID: 7530863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
    Mezvrishvili Z; Managadze L
    Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Systematic review 2007: Primary treatments of testicular germ cell tumors after radical orchydectomy].
    Mottet N; Rousmans S; Culine S
    Bull Cancer; 2008 Feb; 95(2):205-34. PubMed ID: 18330045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
    Pokrivcak T; Lakomy R; Kazda T; Poprach A; Fabian P; Kiss I
    Medicine (Baltimore); 2021 Jun; 100(24):e26381. PubMed ID: 34128899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
    Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
    Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
    Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
    Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.